Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand
- 281 Downloads
ECO-4601 is a structurally novel farnesylated dibenzodiazepinone discovered through DECIPHER® technology, Thallion’s proprietary drug discovery platform. The compound was shown to have a broad cytotoxic activity in the low micromolar range when tested in the NCI 60 cell line panel. In the work presented here, ECO-4601 was further evaluated against brain tumor cell lines. Preliminary mechanistic studies as well as in vivo antitumor evaluation were performed.
Since ECO-4601 has a benzodiazepinone moiety, we first investigated if it binds the central and/or peripheral benzodiazepine receptors. ECO-4601 was tested in radioligand binding assays on benzodiazepine receptors obtained from rat hearts. The ability of ECO-4601 to inhibit the growth of CNS cancers was evaluated on a panel of mouse, rat and human glioma cell lines using a standard MTT assay. Antitumor efficacy studies were performed on gliomas (rat and human), human breast and human prostate mouse tumor xenografts. Antitumor activity and pharmacokinetic analysis of ECO-4601 was evaluated following intravenous (IV), subcutaneous (SC), and intraperitoneal (IP) bolus administrations.
ECO-4601 was shown to bind the peripheral but not the central benzodiazepine receptor and inhibited the growth of CNS tumor cell lines. Bolus SC and IP administration gave rise to low but sustained drug exposure, and resulted in moderate to significant antitumor activity at doses that were well tolerated. In a rat glioma (C6) xenograft model, ECO-4601 produced up to 70% tumor growth inhibition (TGI) while in a human glioma (U-87MG) xenograft, TGI was 34%. Antitumor activity was highly significant in both human hormone-independent breast (MDA-MB-231) and prostate (PC-3) xenografts, resulting in TGI of 72 and 100%, respectively. On the other hand, IV dosing was followed by rapid elimination of the drug and was ineffective.
Antitumor efficacy of ECO-4601 appears to be associated with the exposure parameter AUC and/or sustained drug levels rather than C max. These in vivo data constitute a rationale for clinical studies testing prolonged continuous administration of ECO-4601.
KeywordsDibenzodiazepine Peripheral benzodiazepine receptor (PBR) Cancer Glioma Xenografts
International Association for Assessment and Accreditation of Laboratory Animal Care
Area under the curve
Canadian Council on Animal Care
- CBR; GABAA
Central benzodiazepine receptor
- q3d × 7
Every 3 days for 7 cycles
Mitochondrial permeability transition pore
- q1d × 5
Once daily for 5 consecutive days
Once every other day
Peripheral benzodiazepine receptor
The authors would like to thank Anna Avrutskaya, Robert Mullin and Jennifer Streicker (From Piedmont Reserch Center) and Simon Taylor and Kresimir Pucaj (Nucro-Technics) for performing animal studies. We also thank Mario Chevrette for helpful discussions and revisions.
- 1.Alley MC, Hollingshead MG, Dykes DJ, Waud WR (2004) Human tumor xenograft models in NCI drug development. Cancer Drug Discov Dev 125–152Google Scholar
- 2.Bachmann BO, McAlpine, JB, Zazopoulos E, Farnet CM, Piraee M (2004) Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals. US Patent No. 7,101,872Google Scholar
- 12.Chelli B, Lena A, Vanacore R, Pozzo ED, Costa B, Rossi L, Salvetti A, Scatena F, Ceruti S, Abbracchio MP, Gremigni V, Martini C (2004) Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. Biochem Pharmacol 68:125–134PubMedCrossRefGoogle Scholar
- 14.Corbett T, Polin L, LoRusso P, Valeriote F, Panchapor C, Pugh S, White K, Knight J, Demchick L, Jones J, Jones L, Lisow L (2004) In vivo methods for screening and preclinical testing. Cancer Drug Discov Dev 99–123Google Scholar
- 19.Dimitriadou V, Gourdeau H, Simard B, Boccard S, Pelletier L, McAlpine JB, Zazopoulos E, Falardeau P, Berger F, Farnet CM (2004) Abstract # 569: a new antitumor compound, ECO-4601: preclinical evaluation and in vivo efficacy in glioma. Presented at the 16th EORTC-NCI-AACR symposiumGoogle Scholar
- 24.Hardwick M, Fertikh D, Culty M, Li H, Vidic B, Papadopoulos V (1999) Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 59:831–842PubMedGoogle Scholar
- 29.Maaser K, Hopfner M, Jansen A, Weisinger G, Gavish M, Kozikowski AP, Weizman A, Carayon P, Riecken EO, Zeitz M, Scherubl H (2001) Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer 85:1771–1780PubMedCrossRefGoogle Scholar
- 39.Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M (2006) Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27:402–409PubMedCrossRefGoogle Scholar
- 42.Simard B, Gourdeau H, Bichat F, Mirjolet JF, McAlpine J, Farnet C, Berger F, Falardeau Pu (2005) Abstract # 5896: ECO-4601. A Novel anticancer compound, is a peripheral benzodiazepine receptor ligand and induces apoptosis in gliomasGoogle Scholar
- 48.Venturini I, Alho H, Podkletnova I, Corsi L, Rybnikova E, Pellicci R, Baraldi M, Pelto-Huikko M, Helen P, Zeneroli ML (1999) Increased expression of peripheral benzodiazepine receptors and diazepam binding inhibitor in human tumors sited in the liver. Life Sci 65:2223–2231PubMedCrossRefGoogle Scholar